Neurocrine Biosciences NBIX Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

46.7%+17.8pp

Acadia PharmaceuticalsACAD

37.3%+0.1pp

Crinetics PharmaceuticalsCRNX

-39.2%+14.5pp

Solid Biosciences Inc.SLDB

-57.4%+2.2pp

BiogenBIIB

4.8%-4.3pp

Rhythm Pharmaceuticals, Inc.RYTM

-285.8%-68.9pp

FAQ

What is Neurocrine Biosciences's return on equity?

Neurocrine Biosciences (NBIX) reported return on equity of 22.5% in Q1 2026.

How has Neurocrine Biosciences's return on equity changed year-over-year?

Neurocrine Biosciences's return on equity increased by 81.1% year-over-year, from 12.4% to 22.5%.

What is the long-term trend for Neurocrine Biosciences's return on equity?

Over 5 years (2020 to 2025), Neurocrine Biosciences's return on equity has grown at a -18.7% compound annual growth rate (CAGR), from 46.2% to 16.4%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.